Ambrx, Zhejiang Hisun join forces to develop, co-market bispecifics
By Cornelia Zou
Wednesday, April 30, 2014
HONG KONG Ambrx Inc. and Zhejiang Hisun Pharmaceuticals Co. Ltd. (SH:600267) inked a deal to develop and commercialize bispecifics based on Ambrx's research with an aim to develop new oncology therapies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.